{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nivolumab&page=40", "query": { "intervention": "nivolumab", "page": 40 }, "page_size": 10 }, "pagination": { "page": 40, "page_size": 10, "total_count": 1209, "total_pages": 121, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nivolumab&page=41&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nivolumab&page=39&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T12:18:37.613Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06523621", "title": "Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2025-02-28", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-30T12:18:37.613Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06523621" }, { "nct_id": "NCT04761198", "title": "A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Advanced Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "Etigilimab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mereo BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2021-03-23", "completion_date": "2023-10-30", "has_results": true, "last_update_posted_date": "2025-03-17", "last_synced_at": "2026-10-30T12:18:37.613Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Greenbrae, California • Los Angeles, California + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04761198" }, { "nct_id": "NCT07720284", "title": "An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "High-risk Muscle Invasive Urothelial Carcinoma" ], "interventions": [ { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 915, "start_date": "2026-07-16", "completion_date": "2032-11-23", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-30T12:18:37.613Z", "location_count": 19, "location_summary": "Hot Springs, Arkansas • Little Rock, Arkansas • San Francisco, California + 15 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07720284" }, { "nct_id": "NCT07090148", "title": "Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer Patients", "Non-castrate Prostate Cancer", "Recurrent Prostate Cancer", "Oligometastatic Prostate Cancer (OMPC)" ], "interventions": [ { "name": "pTVG-HP DNA vaccine", "type": "BIOLOGICAL" }, { "name": "Anti-PD-1 monoclonal antibody", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 14, "start_date": "2026-03-03", "completion_date": "2030-10", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-10-30T12:18:37.613Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07090148" }, { "nct_id": "NCT03527108", "title": "Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2020-10-08", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-30T12:18:37.613Z", "location_count": 2, "location_summary": "New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03527108" }, { "nct_id": "NCT03313804", "title": "Priming Immunotherapy in Advanced Disease With Radiation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Immune checkpoint inhibitor", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "John L. Villano, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2017-10-26", "completion_date": "2026-02-16", "has_results": true, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-10-30T12:18:37.613Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03313804" }, { "nct_id": "NCT02400385", "title": "A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "sunitinib", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "California Pacific Medical Center Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-10", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2017-02-01", "last_synced_at": "2026-10-30T12:18:37.613Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02400385" }, { "nct_id": "NCT04021043", "title": "BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Metastatic Carcinoma in the Liver", "Metastatic Carcinoma in the Lung", "Metastatic Malignant Neoplasm in the Thoracic Cavity", "Metastatic Malignant Solid Neoplasm" ], "interventions": [ { "name": "Anti-GITR Agonistic Monoclonal Antibody BMS-986156", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2019-08-19", "completion_date": "2025-04-14", "has_results": true, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-10-30T12:18:37.613Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04021043" }, { "nct_id": "NCT02038933", "title": "Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma. Non-Hodgkin" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2014-03-05", "completion_date": "2020-10-08", "has_results": true, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-10-30T12:18:37.613Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02038933" }, { "nct_id": "NCT04050085", "title": "SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma", "Refractory Pancreatic Adenocarcinoma", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "TLR9 Agonist SD-101", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2019-08-15", "completion_date": "2022-05-14", "has_results": false, "last_update_posted_date": "2023-08-01", "last_synced_at": "2026-10-30T12:18:37.613Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04050085" } ] }